Luciferase reporter assays demonstrated that miR-29b targeted PSME4 that encodes the proteasome activator PA200. Synthetically engineered miR-29b replacements impaired the growth of myeloma cells ...

Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator ...

Proteasomes are protein complexes that break ... but the mechanism of their synergistic activation to mitigate the effects of aging is not well understood. Fortunately, an interesting compound ...